CMYK The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the Recordati group’s activities and therefore, as such, it is not intended as medical scientific indication or recommendation, nor as advertising. A LONG SUCCESS STORY. MORE THAN 90 YEARS OF ACTIVITY.

1926 Recordati was founded in Correggio (Emilia, Italy) Conversion of all savings shares into ordinary shares as “Laboratorio Farmacologico Reggiano” by Giovanni and subsequent 2:1 stock split. Recordati. 2002 The U.K. Control Agency granted a 1927 Launch of Antispasmina Colica®, gastrointestinal Product License (marketing approval) for Zanidip® tract antispasmodic. (lercanidipine) 20 mg tablets.

1930 Launch of Solvobil®, cholagogue and laxative. 2003 The 20mg strength of lercanidipine launched in a number of countries worldwide. 1935 Launch of Tefamin®, cardiotonic, diuretic and antihypertensive, followed by its associations. 2004 The pharmaceutical pipeline is strengthened through the launch of new drugs. 1938 Launch of Simpamina®, of the vegetative nervous system. 2005 Recordati gains access to the largest pharmaceutical market in Europe and the third largest 1953 Recordati moves the company to the current site in worldwide with the acquisition of Merckle Recordati in Milan, the most important Italian economic centre. Germany, now Recordati Pharma. 1956 Launch of Recordil® (efloxate), coronary vasodilator. Establishment of Recordati Pharmaceuticals in the United Kingdom and of Recordati Hellas 1961 An exclusive license agreement is signed, later Pharmaceuticals in Greece. renewed until 2005, with Syntex Corporation (now part of Recordati opens a new active pharmaceutical Roche), at that time at the leading edge of research into ingredients plant in Ireland. the study and synthesis of steroidal hormones. 4:1 stock split.

® 1962 Remeflin (dimefline), respiratory analeptic, 2006 Recordati acquires the Grupo Jaba companies registered and commercialized. in Portugal, today Jaba Recordati. 1973 Flavoxate (Genurin®/Urispas® and other brands), a Zanipress®, a fixed combination of lercanidipine and urinary anti-spasmodic still widely used, was launched. enalapril was approved for sale by BfArM (the German It was the first drug synthesized and developed in Italy to medicines agency). receive FDA approval in the USA. 2007 The first launch of Zanipress®. 1977 Antoral® (tibezonium iodide), an oral antiseptic, Acquisition of Orphan Europe, a European launched in Italy, performs well in a number of countries. pharmaceutical group dedicated to the development, registration, marketing and distribution of unique drugs 1984 The company is listed on the Italian Stock Exchange for the treatment of rare and orphan diseases. (Borsa Italiana, now part of the London Stock Exchange Group). 2008 Acquisition of the French companies FIC and FIC Médical which are dedicated to the registration and ® 1986 Launch of Lomexin (fenticonazole), a the promotion of pharmaceutical products in Russia dermatological and gynecological anti-mycotic, widely and other Commonwealth of Independent States (C.I.S.) used in many countries worldwide. countries. 1995 Recordati outlines its growth and development Acquisition of Yeni Ilaç (today Recordati Ilaç), a strategy embarking on a process of internationalization. well-known pharmaceutical company in Turkey. A subsidiary was established in Spain, now called 2009 Acquisition of Herbacos-Bofarma (today Herbacos Casen Recordati. Recordati), a pharmaceutical company operating in the Czech and Slovak markets. 1997 First launch of Zanidip® (lercanidipine), a new antihypertensive drug entirely discovered and developed 2010 European Marketing Authorization obtained for by Recordati. silodosin (Urorec®, Silodyx®), an alpha blocker indicated for treatment of the signs and symptoms 1999 Recordati acquires the French pharmaceutical of benign prostatic hyperplasia (BPH). company Doms Adrian in France, the second largest ® pharmaceutical market in Europe. Carbaglu (carglumic acid) approved by the Food and Drug Administration (FDA) in the U.S. for the treatment 2000 Expansion in France continues with the acquisition of NAGS deficiency. of the Bouchara pharmaceutical group. Acquisition of ArtMed International in Romania, now Recordati Romania. 2001 The two French companies are merged and the resulting subsidiary becomes Bouchara Recordati. European Marketing Authorization obtained for pitavastatin (Livazo®, Alipza®). IV |

CMYK A LONG SUCCESS STORY. MORE THAN 90 YEARS OF ACTIVITY.

2011 European approval to extend the use of Carbaglu® A license agreement with Gedeon Richter was signed to (carglumic acid) to treat hyperammonaemia due to commercialize cariprazine, a novel atypical antipsychotic. either of the three main organic acidaemias. 2017 Approval of Cystadrops® the first eye-drop solution Acquisition of Dr. F. Frik Ilaç A.S. in Turkey. containing cysteamine hydrochloride approved in the ® Acquisition of Procto-Glyvenol a product indicated for European Union for the treatment of corneal cystine the treatment of haemorrhoids. crystal deposits. Recordati Polska is established in Poland.

Agreement with the Meyer Hospital in Florence (Italy) 2020 ®

Launch of Livazo (pitavastatin) in Spain and in Portugal. for the development of a treatment for pre-term babies | affected by retinopathy of prematurity. 2012 Acquisition of the marketing authorizations, the Acquisition from AstraZeneca the European rights to trademarks and additional assets concerning six OTC Seloken®/Seloken® ZOK (metoprolol succinate) and pharmaceuticals for Germany, the rights to five well- Logimax® (metoprolol succinate and felodipine). known product lines in Russia and other C.I.S. countries, and the leading oral care line of products bearing the Agreement with MimeTech for the development and ­­­­­ Dentosan® trademark in Italy. commercialization of a peptidomimetic of human nerve 1926 growth factor for the treatment of neurotrophic keratitis. Acquisition of Farma-Projekt a Polish pharmaceutical company. Acquisition of three Bayer Consumer Health brands in France, Transipeg®, TransipegLib® and Colopeg®. Recordati acquires all rights to a portfolio of products indicated for the treatment of rare and other diseases 2018 Acquisition from Mylan of the rights to Cystagon® in the United States of America which is now marketed (cysteamine bitartrate), indicated for the treatment of there by Recordati Rare Diseases. proven nephropathic cystinosis. 2013 Acquisition of Opalia Pharma S.A. (now Opalia Acquisition of Natural Point S.r.l., an Italian company Recordati) and its cGMP certified production facility in active in the food supplements market whose main ® Tunisia to establish a direct presence in North Africa. product is Magnesio Supremo . Acquisition of Laboratorios Casen Fleet S.L.U. (now A license obtained from Helsinn for the exclusive rights ® Casen Recordati), a Spanish pharmaceutical company to Ledaga (chlormethine hydrochloride), a novel with headquarters in Madrid and production facilities in gel formulation indicated for the topical treatment of Utebo, Zaragoza. mycosis fungoides, worldwide excluding the United States, China, Hong Kong and Israel. The product has 2014 U.S. Food and Drug Administration (FDA) granted been granted Orphan Drug Designation in Europe and is orphan drug designation for the use of Carbaglu® approved by the European Commission. (carglumic acid) in the treatment of organic acidemias Acquisition of Tonipharm S.A.S., a French company well (OAs). known for its brands Ginkor® based on ginko biloba and License agreement signed with Apricus Biosciences Inc. Alodont®, a line of products used for oral hygiene. for the marketing and sales of Vitaros® (alprostadil), a Launch of Reagila® (cariprazine), a new atypical topical product for the treatment of erectile dysfunction, antipsychotic for the treatment of schizophrenia, and with Plethora Solutions for the commercialization of in Europe. Fortacin™, a topical spray formulation of lidocaine and prilocaine for the treatment of premature ejaculation. 2019 License agreement with Aegerion Pharmaceuticals Inc., for the exclusive rights to commercialize Juxtapid® 2015 Establishment of subsidiaries in Brazil, Mexico (lomitapide), indicated for the treatment of homozygous and Colombia for the commercialization of treatments familial hypercholesterolemia (HoFH), in Japan. for rare diseases. Recordati Rare Diseases, a worldwide leader in rare Carbaglu® (carglumic acid) was authorized for sale by diseases and orphan drugs, becomes the global brand of Health Canada for the treatment of acute and chronic the Recordati’s organization dedicated to treatments for hyperammonaemia due to NAGS deficiency. rare diseases. All companies formerly operating under the name of Orphan Europe were renamed Recordati 2016 Acquisition of Italchimici S.p.A., an Italian Rare Diseases. pharmaceutical company, and Pro Farma AG, now Acquisition from Novartis of worldwide rights to Signifor® Recordati AG, a Swiss pharmaceutical company that ® ® operates also in Austria. and Signifor LAR (pasireotide) for the treatment of Cushing’s disease and acromegaly. Agreement with AP-HP (Assistance Publique – Hopitaux The agreement also covers the acquisition of worldwide de Paris) for the development and commercialization rights to Isturisa® (osilodrostat), an innovative drug for of a product for the treatment of acute decompensation the treatment of endogenous Cushing’s syndrome. episodes in patients affected by Maple Syrup Urine Disease (MSUD). MORE THAN 90 YEARS OF HISTORY

Since 1926, the Recordati group successfully faces the challenges of a market in continuous evolution and identifies fitting business opportunities as they arise. 2 | RECORDATI

RECORDATI A GROWING RENOWNED INTERNATIONAL PHARMACEUTICAL GROUP

The Recordati group grows constantly thanks to the quality of its products and to the implementation of an internationalization policy based on a focused strategy of selective acquisitions and license agreements.

 Recordati is based in Milan, Italy and is listed on the Italian Stock Exchange (London Stock Exchange Group) since 1984.

 Recordati produces and promotes a wide range of innovative products in over 150 countries.

 Recordati’s portfolio includes both products for primary and specialty care and treatments for rare diseases.

 The Group markets a number of specialties generated by its original research.

 The Recordati group is the European partner of leading international pharmaceutical companies. RECORDATI - A GROWING RENOWNED INTERNATIONAL PHARMACEUTICAL GROUP | 3

RECORDATI AND THE MARKET

 With operations in all European countries, in Russia and in the CIS countries, in Turkey and North Africa, in the U.S.A., Canada, Latin America, Japan and Australia, Recordati continues to strengthen its geographical presence.

 Recordati constantly enhances its therapeutic offering through the development of its product pipeline with a focus on rare diseases.

RECORDATI, A GROWING COMMITMENT TO THE TREATMENT OF RARE DISEASES

 The Recordati group works towards improving the quality of life of people suffering from rare diseases together with patients and their families, with doctors and with the support of a highly specialized internal team.

 Recordati develops, produces and sells drugs for the treatment of rare diseases, and operates worldwide in a highly specialized market with a significant growth potential. 4 | RECORDATI

THE RECORDATI GROUP BETWEEN PRESENT AND FUTURE

The proven ability for creating profitable partnerships with important players in the pharmaceutical sector will continue to support the Recordati group in its quest to identify new partners and finalize new license agreements for the development of high value medicinal products.

A WORLDWIDE SUCCESS A GROWING PRESENCE IN NEW MARKETS WE WILL KEEP ON BUILDING

 In the future the Recordati group will continue to focus on the development of its business both TOGETHER by growing its product portfolio and reinforcing its presence in selected markets.

 Recordati will continue to increase its activity in Europe, which is the second largest pharmaceutical market in the world, and to make its products for the treatment of rare diseases available worldwide including the U.S.A., the largest market, Canada, Latin America, Japan and the Asia-Pacific regions.

A RICHER PRODUCT PORTFOLIO

 The launch of innovative new products, the enhancement of its product portfolio with specialties from its own research and development or from targeted license agreements or specific acquisitions, will boost the group’s growth.

 The extensive geographical coverage, an efficient field force of medical representatives and orphan drug specialists, the significant competence in handling regulatory processes, the profound know-how in the handling of highly specialized products, all make the Recordati group an ideal partner for the development and marketing of new products in its markets. THE RECORDATI GROUP BETWEEN PRESENT AND FUTURE | 5

A WORLDWIDE SUCCESS WE WILL KEEP ON BUILDING TOGETHER

CONSTANT INVESTMENT IN RESEARCH AND INNOVATION

R&D EXPENSES  Recordati is committed towards the innovation and marketing Millions of Euro of high value added products and therefore constantly develops 129.7 new medicines and believes research and development is a fundamental basis for its growth. 109.7 100.2

 Dedication and scientific rigor are always behind Recordati’s 83.7 specialties and self-medication products which are also produced 76.7 with the highest levels of quality and safety.

 Recordati’s proven ability to generate profitable alliances with prominent players in the pharmaceutical industry is the basis of an increasingly intense activity in executing new license

agreements for the development of innovative products. 2015 2016 2017 2018 2019 6 | RECORDATI

TODAY’S NUMBERS

2019 was a very favourable year for the group and a number of initiatives were pursued for the company’s future development.

REVENUE 1,481.8 millions of euro

NET INCOME 368.9 millions of euro

NET FINANCIAL POSITION (902.7) millions of euro

SHAREHOLDERS’ EQUITY 1,198.8 millions of euro

DIVIDEND 1.00 euro per share

EMPLOYEES exceed 4,300 TODAY’S NUMBERS | 7

REVENUE EBITDA* EBITDA* Millions of Euro Millions of Euro AS % OF REVENUE 1481.8 1352.2 1288.1 544.0 499.0 1153.9 36.9 454.7 36.7 1047.7 35.3 371.2 32.2 317.0 30.3

2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019

NET INCOME NET INCOME INTERNATIONAL Millions of Euro AS % OF REVENUE BUSINESS GROWTH 368.9 TREND 24.9 312.4 80.6% 288.8 23.1 22.4 79.8% 79.9% 237.4 20.6 198.8 19.0 79.8% 79.4%

2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019

NET INCOME DIVIDEND BALANCE SHEET PER SHARE PER SHARE at 31 December 2019 Euro 1.800 Euro 1.00 0.92 28.81% 20.89% 1.529 0.85 Current Current 1.395 Assets Liabilities 0.70 1.152 36.43% 0.60 0.968 Non- current Liabilities

71.19% 42.68% Non-current Shareholder’s Assets Equity

2015 2016 2017 2018 2019 2015 2016 2017 2018 2019

* Net income before net interest, provision for taxes, depreciation, amortization and write down of both property, plant and equipment and intangible assets. 8 | RECORDATI

GEOGRAPHICAL PRESENCE

SPECIALTY & PRIMARY CARE

n Subsidiaries n Branches and other forms of territorial presence n Countries where Recordati products are sold (under license or export)

EXCEEDS 150 COUNTRIES GEOGRAPHICAL PRESENCE | 9

TREATMENTS FOR RARE DISEASES

n Subsidiaries and direct presence of orphan drug representatives n Commercial agreements and direct delivery

EXCEEDS GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL SALES (First Quarter 2020) 150 COUNTRIES 18.8% Italy ∙ ∙ 6.0% Spain 9.9% France ∙ ∙ 3.1% Portugal 9.4% Germany ∙ ∙ 6.7% Other CEE 8.5% Russia, Ukraine, other CIS ∙ ∙ 5.9% Other Western Europe 7.6% USA ∙ ∙ 2.9% North Africa 6.6% Turkey ∙ ∙ 14.6% Other international sales 10 | RECORDATI

RECORDATI’S SUCCESSFUL PRODUCTS

A number of innovative high value added specialties comprise a large and qualified product portfolio.

The Recordati group:

 makes available to healthcare professionals and patients numerous medicines belonging to various therapeutic areas;

 boasts an important presence in the areas of cardiovascular, urological and psychiatric disorders for which it offers new treatments;

 markets products originated by its own research and by specific license agreements by promoting a wide range of innovative drugs. RECORDATI’S SUCCESSFUL PRODUCTS | 11

PHARMACEUTICAL SALES BY THERAPEUTIC AREA (2019)

∙ 30.8% Cardiovascular ∙ 3.7% Central Nervous System ∙ 23.8% Alimentary tract & metabolism ∙ 2.9% Sensory organs ∙ 13.8% Genito-urinary system ∙ 1.7% ∙ 7.6% Respiratory system ∙ 1.5% Anti-infectives for systemic use ∙ 6.5% Musculo-skeletal system ∙ 1.4% Antineoplastic ∙ 5.3% Blood and blood forming organs ∙ 1.0% Other international sales

COMPOSITION OF REVENUE BY BUSINESS (2019)­­

43.5% Corporate Products 16.9% Treatments for Rare Diseases 18.6% OTC 0.9% Other Revenue 17.0% Subsidiaries’ Local products 3.1% Pharmaceutical Chemicals 12 | RECORDATI’S SUCCESSFUL PRODUCTS

CORPORATE PRODUCTS SPECIALTY & PRIMARY CARE

ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine) antihypertensive ®

SelokenMetoprolol ZOK succinate 1 ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL® (lercanidipine + enalapril) antihypertensive

® ® SelokenMetoprolol ZOK succinate 1 Seloken 1 Metoprolol tartrate UROREC® (silodosin) benign prostatic hyperplasia

®

SelokenMetoprolol ZOK succinate Seloken® 1 1 Metoprolol tartrate LIVAZO®/ALIPZA® (pitavastatin) hypercholesterolaemia

®

BetalocMetoprolol ZOK succinate 1 SELOKEN®/SELOKEN®ZOK/BETALOK®ZOK (metoprolol succinate) ® Betaloc® ZOK Seloken® ZOK Seloken Metoprolol succinate Metoprolol succinate 1 1 1 Metoprolol tartrate angina pectoris, disturbances of cardiac rhythm,

® ® LOGIMAX (metoprolol succinate + felodipine) ® Logimax ® Seloken Felodipine/metoprolol succinate ER Logimax 1 Metoprolol tartrate Felodipine/metoprolol succinate ER antihypertensive

® COLORI SPECIALI CMYK BetalocMetoprolol ZOK succinate 1 P 293 C 100 M 57 Y O K 2 FONT: Arno Pro Semibold Display ® P Cool Gray 10 C C 0 M 0 Y O REAGILAK 60 (cariprazine) antipsychotic ®

BetalocMetoprolol ZOK succinate 1

® ® TERGYNAN gynecological infections

® Logimax Logimax Felodipine/metoprolol succinate ER Felodipine/metoprolol succinate ER

® ® ®

Sodio picosolfato - Magnesio ossido leggero - Acido citrico anidro CITRAFLEET and FOSFOSODA bowel evacuants

POLIDEXA®, ISOFRA® and OTOFA® treatment of ear, nose and throat (ENT) infections REUFLOR®, CASENBIOTIC®, BIORALSUERO®, REUTERI®, GASTRUS® (lactobacillus reuteri protectis) food supplements RECORDATI’S SUCCESSFUL PRODUCTS | 13

Küçük bir hareketle Büyük bir etki! IZ AB LIĞ K I ® 10g Casenlax ORAL ÇÖZELTİ HAZIRLAMAK İÇİN TOZ İÇEREN SAŞE

D R U RD U

Çilek Elma Aromalı Aromalı

BEŞERİ TIBBİ ÜRÜNÜN ADI: CASENLAX 4 g oral çözelti hazırlamak için toz içeren saşe ve CASENLAX 10 g oral çözelti hazırlamak için toz içeren saşe ETKİN MADDE: CASENLAX 4 g oral çözelti hazırlamak için toz içeren saşe: Her bir saşe 4g Makrogol 4000 ve CASENLAX 10 g oral çözelti hazırlamak için toz içeren saşe: Her bir saşe 10 g Makrogol 4000 içerir. ENDİKASYONLARI: CASENLAX 4 g oral çözelti hazırlamak için toz içeren saşe: 6 ay – 8 yaş arası çocuklarda konstipasyonun semptomatik tedavisinde endikedir. Özellikle 2 yaşın altındaki çocuklarda tedaviye başlanmadan önce, herhangi bir organik hastalık varlığı hekim tarafından bertaraf edilmelidir. Konstipasyonun tedavisinde sağlıklı bir diyet ve yaşam tarzı ile birlikte, sadece geçici olarak kullanılmalı. CASENLAX 10 g oral çözelti hazırlamak için toz içeren saşe: Yetişkinler ile 8 yaş ve üzeri çocuklarda konstipasyonun semptomatik tedavisinde endikedir. Tüm laksatiflerde olduğu gibi tedaviye başlanmadan önce, herhangi bir organik hastalık olasılığı dışlanmalıdır. Konstipasyonun tedavisinde sağlıklı bir diyet ve yaşam tarzı ile birlikte, sadece geçici olarak kullanılmalıdır. CASENLAX çocuklarda 3 aydan daha uzun süreli kullanılmamalıdır. Sağlıklı yaşam tarzı ve diyet uygulamasına rağmen konstipasyon devam ederse, altta yatan bir sebepten şüphelenilmeli ve bu durum tedavi edilmelidir. POZOLOJİ: CASENLAX 4 g oral çözelti hazırlamak için toz içeren saşe: Pediyatrik popülasyon: 6 ay – 1 yaş arası: günde 1 saşe; 1 yaş – 4 yaş: günde 1 – 2 saşe; 4 yaş – 8 yaş: günde 2 – 4 saşe . Çocuklarda tedavi 3 ayı geçmemelidir. İntestinal geçişte tedavi ile sağlanan düzelme yaşam tarzı ve diyet değişiklikleri ile sürdürülmelidir. Tedavi kademeli olarak sonlandırılmalı ve konstipasyon tekrarlarsa devam edilmelidir. CASENLAX 10 g oral çözelti hazırlamak için toz içeren saşe: Tercihen sabahları tek doz olarak uygulanan günde 1-2 saşe. Her uygulamadan sonra 125 ml sıvının (örneğin su) içilmesi önerilir. CASENLAX etkisini uygulamadan sonraki 24 - 48 saat içinde gösterir. Günlük dozaj, elde edilen klinik etkiye göre ayarlanmalıdır. Doz; gün aşırı 1 saşe (özellikle çocuklarda) ile günde maksimum 2 saşe uygulanması arasında değişmektedir. Tedavi kademeli olarak sonlandırılmalı ve konstipasyon tekrarlarsa devam edilmelidir. Uygulama şekli: CASENLAX oral olarak uygulanır. Her bir saşe içeriği kullanılmadan hemen önce bir bardak (yaklaşık 125 ml) suda çözünür. Berrak ve şeffaf bir çözelti meydana gelir. Böbrek/Karaciğer yetmezliği: Veri bulunmamaktadır. Pediyatrik popülasyon: CASENLAX 10 g oral çözelti hazırlamak için toz içeren saşe: Tercihen sabahları tek doz olarak, günde 1-2 saşe olarak uygulanır. Her uygulamadan sonra 125 ml sıvının (örneğin su) içilmesi önerilir. Çocuklarda kullanım 3 ayı geçmemelidir. İntestinal geçişte tedavi ile sağlanan düzelme yaşam tarzı ve diyet değişiklikleri ile sürdürülmelidir. Geriyatrik popülasyon: Veri bulunmamaktadır. KONTRENDİKASYONLARI: Etkin maddeye ya da yardımcı maddelerden herhangi birine hipersensitivite, semptomatik stenoz ile ilişkili şiddetli inflamatuvar bağırsak hastalığı (ülseratif kolit, Crohn hastalığı, vs.) veya toksik megacolon, Sindirim sistemi perforasyonu veya perforasyon riski, İleus veya intestinal obstrüksiyon şüphesi, sebebi bilinmeyen ağrılı abdominal sendromlar ÖZEL KULLANIM UYARILARI: Konstipasyonun herhangi bir tıbbi ürün ile tedavisi, aşağıda örneklendirilmekte olan yaşam tarzı ve diyetsel yaklaşımları destekler: Diyette sıvı ve lif alınımının arttırılması, uygun fiziksel aktivite ve bağırsak reflekslerini iyileştirme, diyare durumunda, su ve elektrolit dengesi bozukluğuna yatkın hastalarda (örneğin yaşlı hastalar, karaciğer veya böbrek fonksiyon bozukluğu olan hastalar veya diüretik kullanan hastalar) dikkatli olunmalı ve elektrolit kontrolü düşünülmelidir. Makrogol (polietilen glikol) içeren ürünlerin kullanılması ile hipersensitivite reaksiyonları (kızarıklık, ürtiker, ödem), istisnai anafilaktik şok vakaları bildirilmiştir. Makrogol’ün etki mekanizmasından dolayı CASENLAX ile tedavi sırasında sıvı alınması önerilmektedir. Diğer tıbbi ürünlerin absorbsiyonu, makrogol’ün neden olduğu gastrointestinal geçiş hızındaki artışa bağlı olarak, geçici olarak azalabilir. CASENLAX her bir saşede 0,00064(CASENLAX 4 g) ve 0,0000018 mg (CASENLAX 10 g) sülfür dioksit içermektedir. Bu sülfür dioksit nedeniyle nadir olarak şiddetli aşırı duyarlılık reaksiyonları ve bronkospazma neden olabilir. İLAÇ ETKİLEŞİMLERİ VE DİĞER ETKİLEŞİMLER: Diğer tıbbi ürünlerin absorbsiyonunda geçici azalmalar olabilir. Terapötik indeksi dar olan ilaçların terapötik etkisi değişebilir (ör. antiepileptikler, digoksin ve immünsupresif ilaçlar). GEBELİK VE LAKTASYONDA KULLANIMI Gebelik Kategorisi: C Gebelik dönemi Sistemik maruziyet ihmal edilebilir düzeydedir, dolayısıyla gebelik süresince kullanımında herhangi bir olumsuz tesir beklenmemektedir. Laktasyon dönemi: Emzirme döneminde kullanılabilir. Üreme yeteneği/Fertilite CASENLAX ile herhangi bir fertilite çalışması gerçekleştirilmemiştir. Ancak makrogol 4000 kayda değer bir emilim göstermediğinden, herhangi bir etki beklenmemektedir. Araç ve makine kullanımı üzerindeki etkiler: CASENLAX’ın araç ve makine kullanımı üzerine herhangi bir etkisi yoktur. İSTENMEYEN ETKİLER: Erişkin popülasyon: Yaygın: Abdominal ağrı ve/veya distansiyon, bulantı, diyare Yaygın olmayan: Kusma, acil defekasyon ihtiyacı, fekal inkontinans Çok seyrek: Hipersensitivite reaksiyonları (Kaşıntı, döküntü, yüzde ödem, Quincke ödemi, ürtiker, anafilaktik şok) Bilinmiyor: Eritem, elektrolit bozuklukları (hiponatremi ve hipokalemi) ve/veya dehidratasyon. Pediyatrik popülasyon: Yaygın: Abdominal ağrı, diyare* Yaygın olmayan: Bulantı, kusma, şişkinlik hissi *diyare perianal ağıya neden olabilir. Bilinmiyor: Hipersensitivite reaksiyonları (Anafilaktik şok, anjiyoödem, ürtiker, döküntü, kaşıntı) FARMAKOLOJİK ÖZELLİKLER: ATC kodu: A06AD15 Farmakoterapötik grup: Konstipasyonda kullanılan ilaçlar. Ozmotik laksatifler RUHSAT SAHİBİ: Recordati İlaç San. ve Tic. A.Ş. Ç.O.S.B. Karaağaç Mah. Atatürk Cad. No:36 Kapaklı/TEKİRDAĞ Tel: 0 282 999 16 00 AMBALAJIN NİTELİĞİ VE İÇERİĞİ : Dış tabakası polyester, orta tabakası alüminyum ve iç tabakası polietilen, tek dozluk saşeler. 20 tek-dozlu saşe, hasta Kullanma Talimatı ile birlikte kutu içerisinde ambalajlanır. PERAKENDE SATIŞ FİYATI:

CASENLAX 4 g oral çözelti hazırlamak için toz içeren saşe 20 saşe/kutu 29,90 TL KDV dahil (Şubat 2019) ve CASENLAX 10 g oral çözelti hazırlamak için toz içeren saşe 20 saşe/kutu 41,46 TL KDV dahil (Şubat 2019) RUHSAT TARİH VE NUMARASI: CASENLAX 4 g oral çözelti hazırlamak için toz içeren saşe: 27.07.2017 ve 2017/542 CASENLAX 10 g oral çözelti hazırlamak için toz içeren saşe: CAS/B-2019Q4-02 27.07.2017 ve 2017/543 KÜB’ÜN SON GÜNCELLEME TARİHİ: 11.12.2018 Reçete ile satılır. Ayrıntılı bilgi için lütfen firmamıza başvurunuz.

Gyno-Lomexin Fentikonazol

PROCTO-GLYVENOL® (tribenoside) haemorrhoids

HEXA LINE OF PRODUCTS (biclotymol) antibacterial for infections of the oral cavity

LOMEXIN® /FALVIN® (fenticonazole) antimycotic

CASENLAX®/LAXBENE® and FLEET ENEMA® constipation and bowel cleansing

TRANSACT® LAT (flurbiprofen transdermal patch) anti-inflammatory

URISPAS® /GENURIN® (flavoxate) urinary tract muscle relaxant SELOKEN®/SELOKEN®ZOK/BETALOK®ZOK (metoprolol succinate) angina pectoris, disturbances of cardiac rhythm, hypertension KENTERA® (oxybutynin transdermal patch) hyperactive bladder OXYBUTYNIN TRANSDERMAL PATCH

RUPAFIN®/WYSTAMM® (rupatadine) antihistamine

Lopresor® LOPRESOR® (metoprolol) antihypertensive

PANTONE: 214 C 0 C, 100 M 34 Y, 8K Font: DIN BOLD

ABUFENE® and MUVAGYN® symptoms of menopause

LACDIGEST (tilactase) Lactose intolerance

VITAROS®/VIRIREC® (alprostadil) erectile dysfunction

FORTACIN® (lidocaine+prilocaine) premature ejaculation 14 | RECORDATI’S SUCCESSFUL PRODUCTS

SUBSIDIARIES’ LOCAL PRODUCTS

Some products or product lines marketed locally by Recordati’s subsidiaries detain prominent positions in their markets of reference.

GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL REVENUE (2019)

55.2% Western Europe 14.1% Eastern Europe 9.0% Turkey and North Africa 7.6% USA 14.1% Others

LOSIPACO DUE AZIONI, UN RIMEDIO.

Per l’uso in gravidanza consultare il medico

È un medicinale. Leggere attentamente il foglio illustrativo. Autorizzazione del 04/04/2019 COD. 39763012

pagina ADV.indd 1 15/04/19 09:03 RECORDATI’S SUCCESSFUL PRODUCTS | 15

 In addition to its consolidated presence in the cardio-metabolic area, Recordati in Italy offers innovative treatments in the areas of , , , analgesia as well as food supplements, with the successful commercialization of Magnesio Supremo®, a particular formulation of magnesium is easily assimilated into the body.

 Bouchara Recordati is well known in the French market thanks to a number of prescription and self medication products. It is the exclusive licensee for the production and commercialization of methadone, a synthetic opioid analgesic. The company has also developed an important international presence in the Maghreb area and in French-speaking Africa and Asia where a dynamic export and promotion business distributes its specialties in more than 30 countries.

 Recordati Pharma in Germany supplies first class products to orthopaedic specialists and to gastroenterologists, in particular as related to chronic inflammatory intestinal disorders such as Crohn’s disease and ulcerative colitis.

LOSIPACO DUE AZIONI, UN RIMEDIO.

Per l’uso in gravidanza consultare il medico

È un medicinale. Leggere attentamente il foglio illustrativo. Autorizzazione del 04/04/2019 COD. 39763012

pagina ADV.indd 1 15/04/19 09:03 16 | RECORDATI’S SUCCESSFUL PRODUCTS

 Rusfic, Recordati Ukraine and FIC Médical, our organizations operating in Russia, Ukraine, the other CIS markets and the Central Asia successfully markets products indicated for otorhinolaryngological and vaginal infections which boast a leading position in their markets.

 Casen Recordati in Spain counts on an extensive and substantial portfolio of products, well appreciated in the area of gastroenterology where its products for bowel cleansing and oral rehydration are undisputed market leaders.

 In Turkey Recordati Ilaç markets a diversified product portfolio well appreciated by the practitioner, in the fields of urology, , gynecology and in physical and rehabilitation.

 Opalia Pharma operates in North Africa and in Tunisia, where it is one of the largest local pharmaceutical companies marketing branded generic drugs with leading products in dermatology and in the gastrointestinal and respiratory therapeutic areas.

 Recordati has reinforced its presence in Switzerland with the subsidiary Recordati AG, that has its headquarters in Zug and operates also in Austria, as from 2018 in Sweden, Denmark, Norway, Finland, Iceland with Recordati AB and in BeNeLux with Recordati BV, as from 2019 with Recordati Bulgaria LTD in Bulgaria.

RECORDATI | 17

THE RECORDATI GROUP AND ITS SELF-MEDICATION PRODUCTS

 The Recordati group is also present in the self-medication market segment with well-known brands. It is committed to the improvement of quality of life by offering a choice of successful products.

 Recordati constantly seeks new treatments to offer patients and has further extended its portfolio of OTC products, food supplements and treatments to improve health and well-being.

 All Recordati’s pharmaceutical specialties and self-medication products are characterized by high levels of quality and safety in all countries. 18 | RECORDATI

RECORDATI AND THE TREATMENT OF RARE DISEASES

The acquisition and diffusion of specific scientific knowledge is fundamental for the identification of a rare disease and is of great importance in the research for new .

 Rare diseases bring great suffering to millions of affected people worldwide. A rare disease is defined as a condition that affects fewer than 5 per 10,000 inhabitants in Europe or fewer than 200,000 Americans in the U.S.A..

 There are more than 7,000 known rare diseases but today approved treatments exist for fewer than 10% of these.

RECORDATI AND THE TREATMENT OF RARE DISEASES | 19

The Recordati group operates in the rare disease segment worldwide through its dedicated company Recordati Rare Diseases.

 It develops, produces and markets drugs for the treatment of a number of rare diseases.

 These are marketed directly in Europe, the Middle East, U.S.A., Canada, Russia, Australia, Japan and in some Latin American countries, and through selected partners in other parts of the world. 20 | RECORDATI AND THE TREATMENT OF RARE DISEASES

 Highly trained specialists and a scientific support team collaborate constantly with researchers, medical practitioners and healthcare professionals, with patient groups and families and with regulators to treat and improve the quality of life of people suffering from these diseases worldwide.

 Thanks to a unique distribution system and to specialists dedicated to the promotion and distribution of these products, the group is able to reach patients in their home countries.

The Recordati group makes available to doctors and their patients a team of highly trained specialists and a number of specific drugs. RECORDATI AND THE TREATMENT OF RARE DISEASES | 21

OUR DRUGS FOR RARE DISEASES

NAME ACTIVE INGREDIENT INDICATION

CARBAGLU® carglumic acid Treatment of hyperammonemia due to N-acetylglutamate synthase deficiency (NAGS deficiency) and some organic acidaemias (isovaleric acidaemia, methylmalonic acidaemia and propionic acidaemia)

NORMOSANG® human hemin Treatment of acute attacks of hepatic porphyria PANHEMATIN®

SIGNIFOR® and pasireotide Treatment of Cushing’s disease and acromegaly SIGNIFOR® LAR

ISTURISA® osilodrostat Treatment of endogenous Cushing’s syndrome/Cushing’s disease

COSMEGEN® dactinomycin injectable Treatment of three rare cancers

CYSTADANE® betaine anhydrous Treatment of homocystinuria

CYSTADROPS® cysteamine chlorhydrate Treatment of the ocular manifestations of cystinosis

PEDEA® ibuprofene iv Treatment of patent ductus arteriosus (PDA) The Recordati group makes NEOPROFEN® available to doctors and CYSTAGON® cysteamine bitartrate Treatment of nephropathic cystinosis their patients a team of highly JUXTAPID® lomitapide Treatment of homozygous familial hypercholesterolemia (HoFH) trained specialists and a number ® of specific drugs. LEDAGA chlormethine hydrochloride Treatment of mycosis fungoides, T-cell lymphoma (MF-CTCL) 22 | RECORDATI AND THE TREATMENT OF RARE DISEASES

 Recordati’s commitment to making its products available to patients suffering from rare diseases was recognized by the National Organization for Rare Disorders (NORD) in the U.S.A. with its “Corporate Award”. This important award was granted in 2011 in recognition of the introduction into the United States of Carbaglu®, the first specific treatment approved by the FDA (Food and Drug Administration) for NAGS deficiency, a very rare inherited metabolic disease.

 The important results obtained in improving the diagnosis and management of rare diseases were recognized by EURORDIS (European Organization for Rare Diseases) with an award presented during the celebration of the 2014 Rare Disease Day. The award also distinguishes its established track record in the field of orphan drug development, the establishment of scientific networks, engaging with patient organizations together with its efforts to reduce the impact of disease on the lives of patients.

RECORDATI AND THE TREATMENT OF RARE DISEASES | 23

THE RECORDATI RARE DISEASES FONDATION D’ENTREPRISE

 The Recordati Rare Diseases Fondation d’entreprise targets specialized healthcare professionals and its aim is to improve and to spread currently available knowledge on rare diseases. The organization promotes scientific collaboration, the sharing of experiences and knowledge among sector specialists and the development of new ideas.

 Every year the Academy proposes theoretical and practical courses as well as e-learning online courses which aim to provide , world-wide, with clinically useful and the most up-to-date information concerning current knowledge and recommendations for care.

Recordati is committed to supporting families affected by these diseases through the research and development of new therapies and through the diffusion of specific scientific knowledge within the medical community. 24 | RECORDATI

RESEARCH AND INNOVATION AT RECORDATI

The introduction of new products, both through our discovery programs as well as through alliances with other companies and with research institutes: this is Recordati’s commitment and is a fundamental premise for its growth.

 The Recordati group constantly develops new specialties originated either internally or acquired through development agreements with other pharmaceutical companies and research institutes.

 Commitment, scientific rigor, capability and highly specialized personnel allow Recordati to develop new treatments and to count on an innovative product pipeline.

 Recordati’s research and development activities are mainly focused on generating innovative treatments with a focus on rare diseases. RESEARCH AND INNOVATION AT RECORDATI | 25

PRODUCT DEVELOPMENT PIPELINE

NAME ORIGINATOR INDICATION DEVELOPMENT STATUS

ISTURISA® Novartis Endogenous Cushing’s syndrome/ Approved in Europe. Cushing’s disease Approved in the USA.

CYSTADROPS® Recordati Corneal cysteine crystal deposits Filed in the USA. in patients with cystinosis Development of new formulations in EU and in USA.

REAGILA® Gedeon Richter Schizophrenia Pediatric post-approval development plan.

Metadone Treatment of cancer-related pain Approved in France. in cases of resistance or intolerance to other opioids

CARBAGLU® Orphan Europe Hyperammonaemia due to NAGS Development of new formulations (Recordati) deficiency and to the main organic in EU and USA. acidemias Filed in the USA for the organic acidemias indication.

REC 0438 Recordati/UFPeptides New indications Preclinical development.

REC 0559 Recordati/MimeTech Neurotrophic keratitis Formulation development. Clinical development planning.

REC 0545 Recordati/AP-HP Acute decompensation episodes Formulation development. in MSUD Retrospective study in France and Germany. 26 | RECORDATI

PARTNERING WITH THE RECORDATI GROUP

 Recordati has a strong track record in generating value through partnerships with other pharmaceutical companies, local or global players.

 It is committed to generating further growth through mutually beneficial R&D collaborations, license agreements, acquisitions.

 The Recordati group has commercial operations throughout the European pharmaceutical market and has a strong and growing interest in new markets.

 It has affiliates in Western Europe (Italy, France, Germany, BeNeLux, Portugal, Spain, Switzerland, United Kingdom and Ireland) and in Sweden, in Central Europe (Greece, Poland, the Czech Republic, Slovakia, Romania, Bulgaria), in Russia and the other CIS countries, in Ukraine as well as in Turkey and Tunisia.

 It is also present in the Middle East, in the U.S.A., Canada, Japan, Australia and some Latin American countries with its treatments for rare diseases. PARTNERING WITH THE RECORDATI GROUP | 27

Thanks to its capability in developing successful relationships, Recordati has enacted an intelligent policy of partnering with companies of high standing in the pharmaceutical segment and made targeted acquisitions in markets characterized by high growth potential thus generating value for itself and its partners.

 The group disposes of a strong team of experienced sales and marketing professionals.

 Recordati has proven R&D experience in developing treatments for cardiovascular, urology disorders and rare diseases.

 Its proven capabilities in the management of regulatory procedures and clinical trials in the EU, MENA (Middle East and North Africa) and in the USA make Recordati an ideal partner for the development and commercialization of new products.

 The extensive know-how acquired and dedicated industrial resources allow the company to fully cover the manufacturing chain, from active ingredient to finished product, in its own facilities in Italy, France, Ireland, Spain, Turkey and Tunisia.

 The financial solidity of the group allows it to support targeted R&D investments. 28 | PARTNERING WITH THE RECORDATI GROUP

The Group, which covers almost all of the European pharmaceutical market with a direct presence also in the USA, proposes itself as an ideal partner for the development and commercialization of new products in its territories.

SELECTED PARTNERSHIPS

LICENSOR TRADEMARK ACTIVE INGREDIENT RIGHTS FOR

Aegerion Juxtapid® lomitapide Japan Pharmaceuticals

Almirall Cidine® cinitapride Spain

Amdipharm/ TransAct® LAT flurbiprofene Italy, Portugal Advanz Pharma

Ferring Vitaros®/Virirec® alprostadil Spain, Ireland, Portugal, Greece, Cyprus, International Czech Republic, Poland, Romania, Slovakia, Center Commonwealth of Independent States, Turkmenistan, Ukraine, Georgia, Turkey and African Portuguese-speaking countries

Gedeon Ritcher Reagila® cariprazine Western Europe, some countries in Africa, Turkey

Helsinn Ledaga® chlormethine Worldwide, exc. the United States, China, hydrochloride Hong Kong and Israel

Kissei Urorec®/Silodyx™/ silodosin Europe & Others Silosin®

Kowa Livazo®/Alipza® pitavastatin Europe, exc. UK, Germany

Merck KGaA Cardicor® bisoprolol Italy

Ono-UCB Alprostar® PGE 1 Alpha Italy

Plethora Fortacin™ lidocaine + prilocaine Europe, Russia, Commonwealth of Independent States, Turkey, North Africa

Rottapharm/ Dermatrans®/ nitroglicerine TDS Spain, France Madaus Epinitril®

Sandoz Leptoprol leuproreline France

Takeda Peptazol® pantoprazole Italy

Teva Kentera® oxybutynin TDS 29 European countries

Uriach Wystamm®/Rupafin® rupatadine France, Germany, Italy SUSTAINABILITY FOR THE RECORDATI GROUP | 29

SUSTAINABILITY FOR THE RECORDATI GROUP

As part of its constant dedication to the discovery, development and sale of innovative value-added products with the aim of improving health and quality of life, the Recordati group is committed to research, innovation and quality while creating value for its stakeholders, all of which are distinctive elements of the Group’s corporate social responsibility.

 The Recordati group has initiated a structured and organic sustainability process in line with its strategic, organizational and operational characteristics.

 Recordati operates all over the world in full respect of human rights.

 It manages its relationship with employees, collaborators and suppliers in full respect of the principles and values included in the Group’s Code of Ethics and in accordance with the Conventions of the International Labour Organization in all of the countries in which it operates.

 In addition to ensuring the Group’s development on an international level and focusing on the treatment of rare diseases, the Group, when defining its strategy and operational policies, considers the interests of all stakeholders, taking into account not only the economic, but also the social and environmental impact of its activities.

 Recordati ensures that its success benefits not only patients but also all those who collaborate with the Group: employees, clients, consumers, patients and their associations, investors and the financial community, suppliers and strategic partners. 30 | SUSTAINABILITY FOR THE RECORDATI GROUP

THE RECORDATI GROUP’S STAKEHOLDERS

INVESTORS AND THE GOVERNMENT AGENCIES, AND PATIENTS AND SCIENTIFIC FINANCIAL COMMUNITY REGULATORS, PA DISTRIBUTORS ASSOCIATION ORGANISATIONS AND UNIVERSITIES

EMPLOYEES SUPPLIERS AND LOCAL HEALTHCARE CLIENTS STRATEGIC PARTNERS COMMUNITIES OPERATORS AND CONSUMERS

CORPORATE SOCIAL RESPONSIBILITY ACTIVITIES

Every year Recordati supports a number of associations dedicated to assisting sick people, to the improvement of patients’ quality of life, and to new research projects. Social, cultural and environmental institutions who operate seriously and with passion on a daily basis are generously assisted.

 During 2019 the Recordati group donated approximately € 3 million to foundations, associations, non-profit organizations and medical institutions.

 Recordati supports institutions which offer socially useful services and assistance, for example food and clothing for the homeless in Ireland as well as participating in the «Earth Day Clean Up», or in Germany where some services have been sourced out to the handicapped. SUSTAINABILITY FOR THE RECORDATI GROUP | 31

VITTORE BUZZI CHILDREN’S HOSPITAL IN MILAN Thanks to works entirely financed and directed by Recordati, in November 2019 the Vittore Buzzi Children’s Hospital in Milan opened a new Paediatric Ward and renovated the Paediatric Outpatient Clinic area with rooms specially designed to be child-friendly, also in terms of colours and furnishings. The operation, strongly supported by Recordati, involved a disbursement of approximately € 1.9 million and was dedicated to the memory of Giovanni Recordati. Thanks to the new arrangement, the Paediatric and Paediatric Neurology departments have expanded and differentiated the treatment options for children with acute and chronic developmental neurological diseases. Specifically, the Paediatrics Multiple Operating Unit (UOC), with the opening of the new Single Operating Unit (UOS) Paediatric Ward has 18 new beds, bringing the total number of beds for ordinary hospitalisation up to 38. It will be better able to respond to the growing demand for emergency hospitalization and to implement care and treatment pathways, in scheduled hospitalization regime, for children suffering from chronic/complex disorders who need specialized or ultra-specialized and multidisciplinary assistance. The introduction of two Paediatric Neurology inpatient beds at the new Single Operating Unit (UOS) of the Paediatric Ward and a dedicated area set up in this area with state-of-the-art equipment, will make it possible to treat the main acute and chronic neurological, paediatric diseases.

THE COMMITMENT OF RECORDATI TO IMPROVE ACCESS TO TREATMENTS FOR RARE DISEASES AND MEDICAL ASSISTANCE Recordati shares the principle that every person affected by a rare disease has the right to the best treatment possible and in addition to supporting patient associations and collaborating actively with the medical community to spread the scarce knowledge available, it has developed two separate programmes to provide assistance to patients eligible for financial support for their products in the U.S.A.: the Patient Assistance Program (PAP), valid for all products, and the Co-Pay Assistance Program (CAP). 32 | SUSTAINABILITY FOR THE RECORDATI GROUP

SUSTAINABILITY IN FIGURES

MORE THAN € 1.2 BILLION APPROXIMATELY € 3 MILLION 166 AUDITS of economic value generated and disbursed in donations carried out on suppliers to ensure distributed by the Group in 2019. and contributions in 2019*. product quality and security.

45% 93.5% MORE THAN 110.000 HOURS of the Group’s workforce represented of employees hired on permanent of total training provided by women. contracts. to employees in 2019.

-11% APPROXIMATELY 32 GWH** APPROXIMATELY -6% reduction in water consumption of electricity purchased is obtained tons of CO2 emitted (Scope 2 Location at production facilities compared to from renewable sources and certified based) by the Group’s production 2018. by Guarantees of Origin. plants in 2019.

* In 2019, as well as € 1.64 million disbursed in donations and contributions to foundations, associations, non-profit organisations and medical institutions, the Group also paid out approximately € 1.3 million of the amount allocated in 2017 to the “V. Buzzi” Children’s Hospital in Milan. ** Electricity produced from renewable sources, purchased for the Milan plants and for the Campoverde plant in Aprilia, certified by Guarantees of Origin.

THE RECORDATI GROUP IN THE COVID-19 EMERGENCY Alongside the community in which it operates, right from the beginning, the Recordati group allocated € 5 million to contribute to the support of hospitals and health facilities in their fight against the epidemiologic emergency due to COVID-19 and promptly responded to requests from the Lombardy Region to counter the shortage of antiviral drugs and medicines for obstructive disorders of the respiratory tract by donating 58,920 packs of its own products.

We believe that to contribute to the well-being of the community and allocate a part of our funds to charitable works is not simply a company formality or a professional duty, but rather a moral imperative. It is an imperative which we feel to be an essential part of a healthy company that is not only able to grow, but also at the same time to support and develop the community in which it operates and to give pride to those who work in it. Andrea Recordati SUSTAINABILITY FOR THE RECORDATI GROUP | 33

THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH

The Arrigo Recordati International Prize for Scientific Research was established in the year 2000 in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati who strongly believed in the power of research to drive the development of the pharmaceutical industry and provide products beneficial to .

 The Prize is an international award which aims to promote scientific research.

 An award of 100,000 euros is granted to a scientist in recognition for outstanding work in a particular area of research.

 The winner is chosen by a Jury composed of experts with high international standing.

 The 2019 Award was dedicated to the promotion and recognition of excellence in the research of treatments for rare diseases.

THE 2019 PRIZE This prestigious prize was awarded to Professor Alberto Auricchio, MD, Coordinator of the Molecular Program at the Telethon Institute of Genetics and Medicine (TIGEM) and Professor of at the Department of Advanced Biomedicine, «Federico II» University of Naples, on September 4 during the SSIEM (Society for the Study of Inborn Errors of Metabolism) Congress in Rotterdam. His project was dedicated to research on «Gene therapy of Stargardt disease - the most common inherited macular degeneration in humans - with AAV intein vectors». 34 | RECORDATI

PHARMACEUTICAL CHEMICALS

Recordati uses a broad RECORDATI’S PHARMACEUTICAL range of technologies to CHEMICALS BUSINESS FOCUSES ON: produce competitively maintaining the highest  satisfying the requirements of the pharmaceuticals business, quality standards.  striving for maximum product quality,

 strengthening its presence in highly regulated markets (the United States, Europe and Japan),

 safety of production processes,

 protection of the environment,

 health and safety in the workplace.

PHARMACEUTICAL CHEMICALS (Geographical breakdown of 2019 revenues)

38.6% Europe 32.6% Australasia 26.2% America 2.6% Africa PRODUCTION SITES | 35

PHARMACEUTICAL CHEMICALS PRODUCTION SITES

The Recordati group has a number of production sites: two dedicated to the production of pharmaceutical chemicals, six for pharmaceutical manufacturing and one for the packaging and distribution of treatments for rare diseases.

PHARMACEUTICAL CHEMICAL PLANTS

Recordati’s pharmaceutical chemical production sites are equipped with modern plant and their research laboratories are fitted with the latest equipment.

CAMPOVERDE DI APRILIA (ITALY) ❱ The United States is one of the main markets for its production second only to Europe. ❱ This plant is one of the most important producers in the world of verapamil HCl, ❱ The site covers a surface of 335,000 sq. m with phenytoin, papaverine HCl, dimenhydrinate, a covered area of 35,000 sq.m., it produces tribenoside and manidipine. approximately 650 MT/year of finished goods, it handles internally approximately 5,000 MT/year ❱ In addition to supplying the active ingredients of semi-finished goods are handled internally. for the group’s proprietary specialties, it is also an established independent producer of ❱ A vast range of competencies in the field of organic active ingredients and intermediates for the synthesis allow it to quickly and effectively study pharmaceutical industry internationally. 36 | PRODUCTION SITES

new processes from research right through CORK (IRELAND) to final industrialization. ❱ A dedicated plant built in Cork in Ireland to ❱ The Research and Development laboratories guarantee adequate and continuous supplies of the are fitted with an extremely versatile pilot active ingredient lercanidipine, an important original plant equipped for the small scale production, Recordati drug. in accordance with cGMP (current Good ❱ Automated process control systems ensure constant Manufacturing Practices), of active ingredients. high quality production. ❱ Investments have been made to enhance the ❱ It operates in accordance with GMP (Good technological and production capacity of the plant Manufacturing Practices) and covers a surface area which over the last 7 years has resulted in the of around 43,000 sq. m, with an installed area of installation of more than 20 new reactors, a latest 8,300 sq. m.. generation three stage distillation unit, 2 thin film evaporators and a new anti-acid filter for ❱ It received the 2012 National Energy Efficiency the isolation of solid products. Award which is promoted by the sustainable Energy Authority of Ireland (SEAI) and in 2013 received the ❱ It operates in compliance with current Good European Energy Efficiency Award promoted by the Manufacturing Practices (cGMP) and in conformity Chemical European Federation Industry Council with the most stringent international environmental (CEFIC). regulations. The Plant Environmental Management System is certified according to the UNI EN ISO ❱ In 2016 the site was extended, the two buildings 14001:2004:2015 by Det Norske Veritas Italia (DNV). housing the administration and the quality control laboratories were enlarged. PRODUCTION SITES | 37

PHARMACEUTICAL MANUFACTURING PLANTS

Recordati’s six pharmaceutical production facilities all operate in full compliance with environmental protection regulations and with current Good Manufacturing Practices (cGMP).

ITALY TURKEY The Milan site occupies a surface area of around The Turkish site in Çerkezköy, built on 45,000 sq. m. 5,000 sq. m., built vertically over a number of floors for of land, occupies a surface area of approximately a total of 21,000 sq. m. and produces around 62 million 11,300 sq. m. and currently produces 66 million packages per year. It is specialized in the manufacture packages per year of solid oral and liquid formulations and packaging of solid oral forms, liquids, injectables and products for topical use, of which 20% is dedicated and products for topical use. to third party production. The plant has a production capacity of 80 million packs per year. FRANCE The plant at Saint Victor (France) covers a surface of SPAIN 6,750 sq. m. and produces 33 million packs per year. The Spanish plant is situated near Zaragoza covering It is specialized in the production and packaging of liquid, a surface area of 7,100 sq. m. and produces around solid oral and spray formulations. 19 million packs a year. It is specialized in the production 38 | PRODUCTION SITES

and packaging of solid and liquid oral and topical PACKAGING AND DISTRIBUTION CENTRE formulations. DEDICATED TO PRODUCTS FOR RARE DISEASES In particular, the plant manufactures a line of A new distribution site in Paris exclusively destined to gastroenterological products. Recently, a project was products for the treatment of rare diseases. approved for the installation of a new line for It occupies a surface area of 1,200 sq. m. and is entirely the packaging of tablets in bottles which will increase dedicated to the packaging, storage and shipping the annual volumes by around 7-8 million packs. of rare disease products. An area of 400 sq.m. is office space. TUNISIA The site delivers, upon short notice, more than 27,000 orders annually to more than 60 countries worldwide The Tunisian plant is situated in Ariana, near Tunis. thanks to its highly qualified staff and a modern GMP It covers an area of around 9,100 sq. m. and produces (Good Manufacturing Practices) certified logistics around 17 million packs a year of liquid, semi-solid and platform. oral solid forms for the local market and for some of the countries in the Arabian Peninsula.

CZECH REPUBLIC

The plant in the Czech Republic, situated in Pardubice, produces creams, gels and ointments for a total of 2 million packages per year, some of which for third parties. RECORDATI | 39

THE RECORDATI SHARE

Recordati is listed on the Italian Stock Exchange (London Stock Exchange group) since 1984.

DIVIDEND € 1.00 (per share) € 0.92 € 0.85

€ 0.70 € 0.60 € 0.50

€ 0.33 € 0.30 € 0.30 € 0.27

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

PRINCIPAL SHAREHOLDERS THE RECORDATI SHARE (2019) AT 31 DECEMBER 2019 1.6% Treasury Stok

51.8% Consortium of investment funds Listing: Borsa Italiana, Blue Chip segment, controlled by CVC Capital Partners healthcare

46.6% Free Float ISIN Code: IT 0003828271 Ticker: Bloomberg REC IM, Reuters RECI.MI Index: FTSE MIB FTSE Italia All-Share Pharmaceuticals & Biotechnology Index STOXX Europe 600 Health Care, MSCI ICB Code 4570 Share Capital: n. 209,125,156 common shares Nominal value: € 0.125 per share EPS (diluted): € 1.764 Dividend per share: € 1.00

July 2020

Produced by: Recordati S.p.A. Concept and graphic design: Graphicamente Milano Photos: Archivio Recordati, Niccolò Biddau, Riccardo Sarri, David Fisher Creative Service, Shutterstock images THE GROUP’S OFFICES

ITALY CZECH REPUBLIC MIDDLE EAST Production plant: Autovía Logroño, km. 13.300 RECORDATI S.p.A. AND SLOVAKIA RECORDATI RARE DISEASES 50180 Utebo, Zaragoza HERBACOS RECORDATI S.R.O. MIDDLE EAST FZ-LLC INNOVA PHARMA S.p.A. Ph. + 34 97 646 26 26 Kutnohorská 11/57 Dubai Healthcare City Fax + 34 97 677 15 60 ITALCHIMICI S.p.A. 109 00, Praga 10 - Dolní Mêcholupy Building 25, Unit 206, P.O. Box 505075 Via M. Civitali, 1 - 20148 Milan Ph. +420 227 200 722 Dubai, UAE Ph. +39 02 48787.1 Fax +420 227 200 777 Ph. +971 4 363 5454 SWEDEN Fax +39 02 40073747 www.recordati.cz Fax +971 4 363 5453 RECORDATI AB www.recordati.it Email: [email protected] www.recordatirarediseases.com Jan Stenbecks Torg 17 Email: [email protected] Chemical pharmaceuticals plant: S - 16440 Kista, Svezia Via Mediana Cisterna, 4 FRANCE Ph. +46 8 545 80 230 Fax +46 8 660 50 78 04011 Campoverde di Aprilia (LT) BOUCHARA-RECORDATI S.A.S. MESSICO

Ph. +39 06 92900010 RECORDATI RARE DISEASES S.A. de C.V. Fax +39 06 92904406 LABORATOIRES BOUCHARA SWITZERLAND RECORDATI S.A.S. Av. Insurgentes Sur #1647 Piso 4, NATURAL POINT S.r.l. Oficina 421 Colonia San José Insurgentes, RECORDATI AG Via Pompeo Mariani, 4 - 20128 Milan TONIPHARM S.A.S. Benito Juárez C.P. 03900 Lindenstrasse, 8 - 6340 Baar Ph (+39) 02 27007247 Immeuble “Le Wilson” Distretto Federale, Messico Ph. +41 41 769.1000 Fax (+39) 02 26005099 70, avenue du Général De Gaulle Ph. +525526140975 Fax +41 41 769.1007 www.naturalpoint.it 92800 Puteaux www.recordatirarediseases.com Email: [email protected] Email: [email protected] RECORDATI RARE DISEASES Italy S.r.l. Ph. +33 1 45191000 RECORDATI AG, Via M. Civitali, 1 - 20148 Milan Fax +33 1 47560246 RARE DISEASES BRANCH Ph. +39 02 4878 7173 www.recordati.com POLSKA Uferstrasse, 90 4057 Basilea Fax +39 02 4878 7174 Production plant: RECORDATI POLSKA SP. Z O.O. Ph. + 41 61 205 61 00 www.recordatirarediseases.com Parc Mécatronic - 03410 Saint Victor Ul. Królewska, 16 - 00-103 Varsavia www.recordatirarediseases.com Email: [email protected] Ph. +33 4 70037900 Ph. +48 22 206 84 50 Fax +33 4 70037890 www.recordatipolska.pl AUSTRALIA RECORDATI RARE DISEASES SARL TUNISIA RECORDATI RARE DISEASES Immeuble “Le Wilson” PORTUGAL OPALIA PHARMA S.A. 70, avenue du Général De Gaulle AUSTRALIA PTY Ltd JABA RECORDATI S.A. OPALIA RECORDATI SARL Level 6, 69 Reservoir Street 92800 Puteaux Z.I. Kalaat El Andalous - 2022 Ariana Surry Hills, Sidney Ph. +33 1 47 73 64 58 CASEN RECORDATI PORTUGAL Ph. +216 70 559 070-064 New South Wales 2010 Fax +33 1 49 00 18 00 UNIPESSOAL LDA Fax +216 70 559 184 Ph. +61 (0) 2 8218 2115 www.recordatirarediseases.com BONAFARMA - PRODUTOS www.opalia-pharma.com www.recordatirarediseases.com Email: [email protected] FARMACÊUTICOS S.A. Email: [email protected] Email: [email protected] JABAFARMA - PRODUTOS GERMANY FARMACÊUTICOS S.A. TURKEY BRASIL RECORDATI PHARMA GmbH Av. Jacques Delors RECORDATI ÍLAÇ RECORDATI RARE DISEASES Eberhard-Finckh-Str. 55 - 89075 Ulm Ed. Inovação 1.2, Piso 0 - Taguspark ve Hammaddeleri Sanayi ve Ticaret A.S. COMERCIO DE MEDICAMENTOS LTDA Ph. +49 731 7047.0 2740-122 Porto Salvo Maslak Mahallesi. Sümer Sokak, Av. Piraíba, 296 - 9 - Parte B - Fax +49 731 7047.297 Ph. +351 21 4329.500 Maslak Office Building No: 4 Kat: 5-6 Centro Comercial Jubran www.recordati.de Fax +351 21 9151.930 34398 Maslak Sarıyer/ Istanbul 06460-121 Barueri - São Paulo RECORDATI RARE DISEASES GmbH www.jaba.pt Ph. +90 212 401 91 00 Ph. +55 11 4414-5851/5852 Eberhard-Finckh-Str. 55 Fax +90 212 401 91 10 www.recordatirarediseases.com 89075 Ulm, Germania ROMANIA www.recordati.com.tr Email: [email protected] Ph. +49 731 140 554 0 RECORDATI ROMANIA S.R.L. Fax +49 731 140 554 99 Pharmaceutical plant: www.recordatirarediseases.com 92-96 Izvor street, Forum III Building, Çerkezköy Organize Sanayi Bölgesi BENELUX Office B, 4th floor, Rooms 2-8, 5th Email: [email protected] Karaağaç Mahallesi Atatürk RECORDATI BV or SRL District, Bucarest Caddesi No:36 Kapaklı, Avenue du Bourgmestre Demunter 5, Ph. +40 21 667 17 41 - 2 JAPAN 59510 Tekirdağ Istambul 1090 Jette, Belgium Fax +40 31 405 57 42 Ph. +90 282 999 16 00 Tel: +32 2 461.01.36 RECORDATI RARE DISEASES JAPAN KK www.recordati.ro Fax +90 282 999 16 61 Fax +32 2 461 02 36 1-10-2, Ichibancho, Chiyoda-ku, www.recordati.com Tokyo, 102-0082 RUSSIA AND C.I.S Email: [email protected] Ph. +81 3 4510 2910 UKRAINE Fax +81 3 4510 2911 FIC MEDICAL S.a.r.l. RECORDATI UKRAINE LLC Immeuble “Le Wilson” BULGARIA www.recordatirarediseases.com 40, Hlybochytska Str. - Kyiv 04050 Email: [email protected] 70, avenue du Général de Gaulle Ph. +380 44 351 18 63 RECORDATI BULGARIA Ltd 92800 Puteaux, Francia Fax +380 44 351 18 64 84 “Al. Stamboliiski” Blvd, Ph. +33 1 45 19 11 00 GRECIA www.recordati.com Floor 8, Office No. 44 - 1303 Sofia Fax +33 1 45 19 10 83 Ph. +359 2 829 39 37 RECORDATI HELLAS RUSFIC LLC UNITED KINGDOM Mob. +359 877 784 500 PHARMACEUTICALS S.A. Area №IAZH, 6 floor, 7 entrance, WTC RECORDATI PHARMACEUTICALS Ltd www.recordati.com 7, Zoodochou Pigis str Krasnopresnenskaya Naberezhnaya 12 Origin, Western Road Email: [email protected] 15231 K. Chalandri, Atene Moscow, Russian Federation, 123610 Bracknell RG12 1US Ph. +30 210 6773822 Ph. +7 495 2258 001 Ph. +44 1 49 1576 336 CANADA Fax +30 210 6773874 Fax +7 495 2582 007 www.recordati.com Email: [email protected] RECORDATI RARE DISEASES Primary and specialty care: CANADA Inc. www.rusfic.ru 3080 Yonge Street, Suite 6080 IRELAND Email: [email protected] USA RECORDATI RARE DISEASES Inc. Totonto, Ontario - Canada M4N 3N1 RECORDATI IRELAND Ltd Rare Diseases: 100 Corporate Drive, Suite 104 Ph. +1 647 255 8830 Raheens East www.recordatirarediseases.com Lebanon, NJ 08833 Fax +1 647 255 8801 Ringaskiddy Co. Cork Email: [email protected] www.recordatirarediseases.com/ca Ph. +353 21 437 94 00 Ph. +1 908 236 0888 Email: [email protected] Fax +353 21 437 92 64 Fax +1 908 236 0028 www.recordati.com SPAIN www.recordatirarediseases.com Email: [email protected] COLOMBIA CASEN RECORDATI S.L. RECORDATI RARE DISEASES Vía de las Dos Castillas, 33 3° COLOMBIA S.A.S. Ática Edificio 7 Carrera 7 N° 127 – 48 Oficina 901 28224 Pozuelo de Alarcòn, Madrid Edificio 128 Centro Empresarial Ph. + 34 91 351 88 00 Bogotá D.C. Ph. + 34 91 659 15 50 Ph. +57 1 6472780 – 57 1 6474316 Fax + 34 91 351 87 99 www.recordatirarediseases.com www.casenrecordati.com Email: [email protected]